The latest Investing Matters Podcast with Jean Roche, Co-Manager of Schroder UK Mid Cap Investment Trust has just been released. Listen here.
I very much doubt he knew there would be a major seller.
Whenever you get stuck in a share you hope he'll promote your company so you can get out and some other poor sucker takes your place.
I read it that the mm's had cleared £3m, and had a further £1.5m to go. The ORPH stock hadn't been transferred, but was being worked. That was my take, but I guess we'll find out.
Normally from my experience when the placing is announced the market fairly quickly adjusts to factor in the extra shares, so there should be no further adjustment once the placing is approved or the shares are issued. I'm sure this recent drop is unrelated to the placing, and as CF said the next tranche are being taken up by II's with sticky fingers I can't see a further drop. Once this seller is cleared the price will go back up above 15p in no time imo.
Why would I ask strictlync about what you posted? Are you the same person? I don't think I'm the one with a problem. Why are you filling this board with made-up rubbish?
What are you on about moniman you absolute plum.
Friday's always a bad news day. I'd expect tomorrow or Monday.
Majorboy - major feckin eejit.
My interpretation of this is we may be due for a 20p per share dividend payment in the next couple of months, which makes todays share price look pretty attractive to say the least.
You may’ve seen that Merck recently acquired Themis, a very similar company to Imutex, and the final price hasn’t been disclosed yet but merger market says between €100m and €500m cash and we're lead to believe it was closer to €500m...... We feel there's at least 6 or 7 other similar large vaccine companies such as Norvartis, Pfizer, Sanofi etc and who will now copy Merck and potentially acquire a company such as Imutex. I've always said that this is a non-core asset and we’ll either sell it for cash or spin it in to a Nasdaq listed vehicle where all existing Open Orphan shareholders will receive a dividend specie whether it’s for a cash consideration or shares in the Nasdaq vehicle. Which if one does the sums could be very considerable.
Anything disclosed after hours shows as a buy or sell depending upon the closing mid price, even if it's days old. I don't know how the market makers get away with hiding such big trades for so long. It's price sensitive information in it's own right. If companies acted like this they'd be investigated by the FCA! Or at least you would hope they would be.
It's obviously a sell, fwiw.
I think it will go back up tomorrow morning biglad6. One thing I won't do is risk selling to buy back cheaper - but you do so if you wish (assuming you already hold any of course).
Looks like a sell from Friday. At least it's cleared and gone. Hopefully the price'll go back up now.
The press launch went really well, and please note we are targeting B2B for antibody testing i.e. large employer groups, where we can do on demand large numbers of tests in a short period of time and get paid very well providing this quick and efficient service. As such, a lot of our press campaign was targeted to the HR managers, CEO's, COO's etc and not to the general population, because we don't want to get swamped with individual requests for antibody testing as that's simply not the model we want to follow. As said, doing large amounts for one group at a time is a much more attractive business model for us, therefore we weren't targeting mass media coverage on Thursday but all the same it went very well and we have received an awful lot of inbound queries from our target employer groups and will be actively working through that in the days and weeks ahead.
https://www.worldometers.info/coronavirus/country/iran/
Second peak gotabesirius. Check out the daily new cases. Looks like it's going to keep coming back until it's stopped.
'The Covid-19 play is over', says trader250. Idiot. Take a look at what's happening in Mexico, India and Brazil, factor in what's happening in Iran, then have a little think.
I think Northseatiger has a point. If a few traders got caught out by an intraday RNS it might strengthen the share price for a while.
?
I'm not really sure that you should be promoting the type of antigen test Avacta do on this bulletin board hants. But to answer your specific points, firstly even the PM and Health Secretary have said the key to getting back to work is the antibody test.
To my knowledge, only one person (from South Korea I believe) was thought to have caught Covid-19 a second time, although it seems the first time was counted twice, so there does seem to be some immunity.
You may well have a point about the antibody passport, but I believe it would do more good than harm.
If 20% of the workforce could safely go back to work, as is suspected in parts of the country, it could mean the difference between companies surviving or folding. It would mean there could be some return to normality.
The antigen test only helps point out if you currently have Covid-19 of course, not if you've had it. There's a place for both, but the antibody test is far from being a tool to help with statistics, it's the test that will get the country working again.
Are you taking the Michael hants? I do know the difference.
CF suggested from the experts he's spoken to that there will be 3 years immunity approximately, although that of course hasn't been proven, perhaps longer if a vaccine is used.
Surely you know antigen tests have been around a lot longer than antibody tests. After all, you are invested in AVCT.